Tesamorelin: Uses, Benefits, and Who It's FDA-Approved For

Short answer: Tesamorelin's only FDA-approved use is reducing excess abdominal fat in adults with HIV-associated lipodystrophy (Egrifta / Egrifta SV / Egrifta WR). Longevity and cognition marketing is off-label. One positive 2012 cognition pilot exists; a larger recent HIV trial found a more mixed cognitive signal — not a clean replication.

Tesamorelin gets marketed in longevity circles for cognitive benefits and body composition — but its actual FDA approval is for something much narrower, and the cognition evidence is thinner and more mixed than the marketing suggests. Here's what's approved, what's been studied, and what's still genuinely uncertain.

What Tesamorelin Actually Is and What It's FDA-Approved For

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release the body's own growth hormone.^[1]

Its sole FDA-approved indication — under the brand name Egrifta (and its reformulated successors Egrifta SV and Egrifta WR) — is the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.^[1] The FDA first approved tesamorelin for this indication on November 10, 2010, making it the first, and still the only, FDA-approved treatment for HIV-associated lipodystrophy.^[2]

That approval was based on two Phase 3, multicenter, randomized, double-blind, placebo-controlled trials totaling 816 HIV-infected patients with excess abdominal fat — a 26-week main phase plus a 26-week extension — which showed statistically significant reductions in visceral adipose tissue and waist circumference versus placebo.^[1]

Since then, the FDA has approved two reformulated versions with the same approved indication: Egrifta SV in 2019 and Egrifta WR in 2025. Both were designed to reduce injection volume and reconstitution frequency — not to expand what the drug is approved to treat.^[2]

What the Evidence Shows for Cognitive Function

The most-cited study supporting off-label cognitive use is a 20-week, randomized, double-blind, placebo-controlled trial of 152 adults aged 55–87 — including both cognitively healthy older adults and adults with mild cognitive impairment. It found tesamorelin produced statistically significant improvements in executive function, with a trend toward improved verbal memory, compared to placebo.^[3] The benefit was comparable in magnitude between the mild-cognitive- impairment group and the healthy older-adult group, and the study authors explicitly called for longer trials to further examine the drug's potential for brain health during aging.^[3]

That's a genuinely positive finding — but it's worth knowing this remains essentially the onlyrandomized, placebo-controlled trial testing tesamorelin specifically for cognitive outcomes in an aging population, and its signal hasn't been independently replicated in a comparably designed trial since.

A more recent, larger trial specifically in older adults living with HIV adds real nuance rather than a clean answer either way. It found tesamorelin significantly reduced waist circumference, as expected from its approved mechanism — but on the between-group cognitive comparison against standard of care, the difference wasn't statistically significant. Looked at withineach group separately, though, the tesamorelin group showed a statistically significant cognitive improvement over the study period, while the standard-of-care group's change did not reach significance.^[4]That's not the same as a flat negative result, but it's also not the clean positive signal the earlier trial suggested — a genuinely mixed picture that complicates simple extrapolation from the original pilot.

Side Effects

In the original 2012 cognition trial, adverse events were reported by 68% of tesamorelin-treated participants versus 36% of placebo-treated participants — though all reported adverse events were characterized by the study authors as mild.^[3]

For the FDA-approved lipodystrophy indication specifically, the most commonly reported adverse reactions (occurring in more than 5% of patients) per the prescribing label are arthralgia (joint pain), injection-site redness, injection-site itching, pain in the extremities, peripheral edema (swelling), and myalgia (muscle pain).^[1]

Comparing providers? Seegrowth-hormone peptide prices across Longevity providerson RENVA's Longevity hub.

The Bottom Line

Tesamorelin has one narrow, well-established FDA approval — reducing visceral fat in HIV-associated lipodystrophy — backed by large, solid trials. Everything else it's marketed for in the longevity space is off-label, and the cognitive evidence specifically is thinner than it might appear: one genuinely positive pilot trial, and one larger, more recent trial that found a more complicated, partial signal rather than a clear replication. If cognitive benefit is your main reason for considering tesamorelin, that's a smaller and less settled evidence base than its approved use for fat reduction.

Frequently Asked Questions